Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Teva and AbCellera collaborate once again for monoclonal antibodies

Executive Summary

In the second collaboration between AbCellera Biologics Inc. and Teva Pharmaceutical Industries Ltd., AbCellera agreed to once again apply its proprietary monoclonal antibody (mAb) screening platform to discover antibodies that modulate the function of an undisclosed membrane protein chosen by Teva.
Deal Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register